By Fineline Cube Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) has received IND approval from China’s National Medical Products Administration (NMPA) to initiate a Phase I clinical trial of GLR2037, its Category 1 chemical drug and first-in-class androgen receptor–proteolysis-targeting chimera (AR PROTAC), in patients with advanced prostate cancer.
GLR2037 represents a strategic entry into the next generation of oncology therapeutics, leveraging PROTAC technology—an emerging modality that hijacks the cell’s ubiquitin-proteasome system (UPS) to selectively degrade disease-causing proteins previously deemed “undruggable” by conventional small-molecule inhibitors.
Development & Regulatory Status
| Attribute | Detail |
|---|---|
| Drug Name | GLR2037 |
| Classification | NMPA Category 1 (novel chemical entity) |
| Modality | Androgen Receptor (AR)–targeting PROTAC |
| Indication | Advanced prostate cancer (castration-resistant and metastatic forms) |
| Trial Phase | Phase I (first-in-human, dose escalation) |
| Regulatory Milestone | NMPA IND clearance granted Q2 2026 |
| Global Context | Among the first AR PROTACs to enter clinical development outside the U.S. |
Scientific Rationale
- Mechanism: Unlike traditional anti-androgens that merely block AR signaling, GLR2037 induces complete degradation of the androgen receptor, eliminating both genomic and non-genomic AR functions.
- Target Scope: Addresses key resistance mechanisms in late-stage prostate cancer, including AR splice variants (e.g., AR-V7) and overexpressed full-length AR—targets inaccessible to current therapies like enzalutamide or abiraterone.
- Platform Potential: Success would validate Gan & Lee’s internal PROTAC discovery engine, opening pathways to target other oncogenic transcription factors.
Competitive & Strategic Implications
- Market Need: Over 150,000 new prostate cancer cases annually in China, with limited options after second-line hormonal therapy failure.
- Differentiation: GLR2037 joins a global race led by Arvinas (ARV-110) and Kyowa Kirin, but is the first domestically developed AR PROTAC in China, positioning Gan & Lee as a pioneer in targeted protein degradation in Asia.
- IP Position: Backed by composition-of-matter and method-of-use patents filed in China, U.S., and EU.
- Pipeline Impact: Positive data could accelerate partnerships with multinational pharma seeking China-accessible degraders.
Forward-Looking Statements
This brief contains forward-looking information regarding clinical development and regulatory progress. Actual results may differ due to trial outcomes, safety findings, and competitive dynamics.-Fineline Info & Tech